Luminex Corporation (LMNX)
| Market Cap | 1.75B |
| Revenue (ttm) | 437.66M |
| Net Income (ttm) | 23.13M |
| Shares Out | 45.89M |
| EPS (ttm) | 0.50 |
| PE Ratio | 73.57 |
| Forward PE | n/a |
| Dividend | $0.38 |
| Dividend Yield | 1.03% |
| Trading Day | May 7 |
| Last Price | $36.86 |
| Previous Close | $36.91 |
| Change ($) | -0.05 |
| Change (%) | -0.14% |
| Day's Open | 36.88 |
| Day's Range | 36.81 - 36.99 |
| Day's Volume | 648,407 |
| 52-Week Range | 20.47 - 41.25 |
NEW YORK, April 16, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class A...
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Luminex Corporatio...
Luminex (LMNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
NEW YORK, April 13, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Luminex Corporation (NASDAQ: LMNX) concerning potent...
NEW YORK, April 12, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Luminex Corporation (NASDAQ: LMNX) and its board of directors concerning the proposed acq...
Investors reacted favorably over the announcement that Saluggia, Italy-based DiaSorin SpA (MIL:DIA) is paying $1.8 billion to purchase Austin, Texas-based Luminex Corp. (NASDAQ:LMNX), a developer of pro...
NEW YORK, April 12, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Luminex Corporation ("Luminex" or the ...
MILWAUKEE, April 12, 2021 /PRNewswire/ -- Ademi LLP is investigating Luminex (NASDAQ: LMNX) for possible breaches of fiduciary duty and other violations of law in its transaction with DiaSorin. Click he...
SALUGGIA, Italy, April 11, 2021 /PRNewswire/ -- DiaSorin S.p.A. ("DiaSorin"; FTSE MIB: DIA) today announced that its Board of Directors has unanimously approved and signed a definitive merger agreement ...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Luminex Corporation (NASDAQ: LMNX) to DiaSorin S.p.A. for $37.00 per share is fair to...
Investor confidence is high in Luminex (LMNX) stock, courtesy of its solid prospects.
Luminex (LMNX) develops the combined assay to rapidly deliver clear solutions about respiratory infections from a single test.
Luminex (LMNX) reported earnings 30 days ago. What's next for the stock?
AUSTIN, Texas, March 10, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has submitted an Emergency Use Authorization application to the U.S. Food and Drug Administration...
AUSTIN, Texas, March 9, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that Homi Shamir, Chairman, CEO & President, and Harriss Currie, Senior Vice President and CFO, plan to pa...
Luminex (LMNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
AUSTIN, Texas, March 4, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) fo...
Investor confidence is high in Luminex (LMNX) stock, courtesy of its solid prospects.
Luminex Corporation (NASDAQ: LMNX) has received $11.3 million in funding from the Biomedical Advanced Research and Development Authority (BARDA). It will support the rapid development and validation of ...
AUSTIN, Texas, Feb. 19, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received $11.3 million in funding from the Biomedical Advanced Research and Development Author...
Luminex (LMNX) witnesses total sample-to-answer molecular diagnostics revenue growth in the fourth quarter.
Luminex (LMNX) delivered earnings and revenue surprises of -92.86% and 0.35%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Luminex (NASDAQ:LMNX) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 85.71% over the past year to $0.01, which missed the estimat...
AUSTIN, Texas, Feb. 8, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced results for its fourth quarter and full-year ended December 31, 2020. All amounts in this release are in co...
AUSTIN, Texas, Feb. 8, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company") today announced that its board of directors declared a cash dividend for the first quarter of 2021 of $0.10 ...
AUSTIN, Texas, Jan. 13, 2021 /PRNewswire/ -- As previously announced, Luminex Corporation (Nasdaq: LMNX) will present at the 39th Annual J.P. Morgan Healthcare Conference, to be held virtually today, Ja...
AUSTIN, Texas, Jan. 12, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced 4th quarter 2020 revenue of approximately $111M, up approximately 23% over the 4th quarter of 2019 and ful...
AUSTIN, Texas, Dec. 16, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced that Nachum "Homi" Shamir, Chairman, CEO and President, and Harriss Currie, Senior Vice President and CFO,...
AUSTIN, Texas, Dec. 7, 2020 /PRNewswire/ -- On December 3, 2020, Luminex Corporation (Nasdaq:LMNX) (the "Company"), announced that its board of directors approved a $0.01 increase in the quarterly divid...
Luminex (LMNX) reported earnings 30 days ago. What's next for the stock?
These are the stocks seeing the most insider buying this week
Brian Sullivan on the top companies this week whose executives are purchasing their own stock, on Worldwide Exchange.
Luminex (LMNX) witnessed total sample-to-answer molecular diagnostics revenue growth in the third quarter.
Luminex Corporation's (LMNX) CEO Homi Shamir on Q3 2020 Results - Earnings Call Transcript
Luminex (LMNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AUSTIN, Texas, Oct. 22, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the third quarter ended September 30, 2020 on Thursday, November 5, 20...
AUSTIN, Texas, Oct. 7, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced 3rd quarter 2020 revenues of approximately $106 million, up approximately 35% over the 3rd quarter of 2019....
Investor confidence is high on Luminex (LMNX) stock, thanks to solid prospects.
AUSTIN, Texas, Sept. 24, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received a $5,389,813 award from the Biomedical Advanced Research and Development Authority (...
AUSTIN, Texas, Sept. 23, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received an award of $683,500 from the Biomedical Advanced Research and Development Authority...
AUSTIN, Texas, Sept. 15, 2020 /PRNewswire/ -- On September 10, 2020, Luminex Corporation (Nasdaq:LMNX) (the "Company"), announced that its board of directors declared a cash dividend for the third quart...
Luminex (LMNX) reported earnings 30 days ago. What's next for the stock?
Blame it on Abbott.
Luminex (LMNX) witnessed total sample-to-answer molecular diagnostics revenue growth in Q2
Luminex Corporation (LMNX) CEO Nachum Shamir on Q2 2020 Results- Earnings Call Transcript
Luminex (LMNX) delivered earnings and revenue surprises of 237.50% and -0.07%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Luminex sees its Relative Strength Rating reach the elite 90-plus level. The post Luminex Scores Relative Strength Rating Upgrade appeared first on Investor's Business Daily.
Shares of Luminex (NASDAQ:LMNX) moved higher by 6.77% in after-market trading after the company reported Q2 results.
AUSTIN, Texas, Aug. 4, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced the retirement of its Chairman, G.
Nate Pile — the editor of growth stock advisory Nate's Notes has just released the first issue of a new advisory service focused on retirement investing, The Little River Investment Guide. The advisor r...
About LMNX
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a sof... [Read more...]
| Industry Medical Instruments & Supplies | IPO Date Mar 30, 2000 |
| CEO Nachum Shamir | Employees 1,325 |
| Stock Exchange NASDAQ | Ticker Symbol LMNX |
Analyst Forecasts
According to 5 analysts, the average rating for Luminex stock is "Hold." The 12-month stock price forecast is 34.50, which is a decrease of -6.40% from the latest price.